The long-term curative effect of Express in treating rheumatoid arthritis is higher than that of Humira, and the Phase 3 clinical results of AbbVie JAK inhibitor are positive

▎Editor of WuXi AppTec Content Team On June 2, 2021, AbbVie announced that the JAK inhibitor Rinvoq (upadacitinib) has reached the primary endpoint and secondary end point in a phase 3 clinical trial for patients with moderate to severe rheumatoid arthritis To the end.

The trial results showed that the Rinvoq/MTX combination maintained a higher clinical remission rate and lower disease within 3 years compared with Humira/methotrexate (MTX) treatment Activity (low disease activity), more than a quarter of patients achieve clinical remission at 3 years.

In addition, a comprehensive safety analysis found that Rinvoq had consistent safety characteristics during the 4.
5-year follow-up period, and no new safety risks were observed.

More than 70% of patients with moderate to severe rheumatoid arthritis do not meet the clinical remission criteria, so the results of this trial are very encouraging.

The detailed data of the test will be announced at the EULAR 2021 virtual conference.

Rinvoq is a selective JAK inhibitor taken orally once a day and is being studied in several immune-mediated inflammatory diseases.

JAK family proteins play an important role in the pathophysiological process of immune-mediated diseases.
In human cell experiments, Rinvoq preferentially inhibits JAK1 signal transduction.

In August 2019, Rinvoq was approved by the U.
S.
Food and Drug Administration for the treatment of moderate to severe adult patients with active rheumatoid arthritis who are inadequate or intolerant to methotrexate.

Previously, AbbVie had announced that after 12 weeks of treatment, the results of the phase 3 clinical trial SELECT-COMPARE showed that Rinvoq reached the primary endpoint of ACR20 response and clinical remission.

The data released today show that compared with the active control group, the test group has a higher proportion of patients achieving and maintaining clinical remission and low disease activity in 3 years.
Please see the figure below for specific data.

▲Long-term efficacy data of Rinvoq in the SELECT-COMPARE trial (picture source: reference [1]) Rheumatoid arthritis is a chronic and debilitating immune-mediated inflammatory disease, with an estimated 23.
7 million people worldwide People are affected by it.

As the most common autoimmune arthritis, it causes joint pain, stiffness, swelling and loss of function.

Many patients with rheumatoid arthritis still have not achieved clinical remission or low disease activity goals.

"We are committed to helping more rheumatoid arthritis patients reach their treatment goals, aimed at alleviating or reducing disease activity.

" said Dr.
Mudra Kapoor, head of Rheumatology, AbbVie's Global Medical Affairs.
"These data prove The effectiveness and safety of using Rinvoq for long-term treatment of rheumatoid arthritis.

We will continue to advance research to provide valuable insights into the role of Rinvoq in helping patients with moderate to severe rheumatoid arthritis.

"Reference: [1] New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress.
Retrieved June 2, 2021, from https://news.
abbvie.
com/news/press-releases/new-long-term-efficacy-and-safety-analyses-evaluating-rinvoq-upadacitinib-in-patients-with-rheumatoid-arthritis-to-be-presented-at-eular-2021- virtual-congress.
htm[2] AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress.
Retrieved June 2, 2021, from https://news.
abbvie.
com /news/press-releases/abbvie-to-present-analysis-evaluating-continuous-rinvoq-upadacitinib-treatment-in-psoriatic-arthritis-for-more-than-one-year-at-eular-2021-virtual-congress .
htm Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.

If you need guidance on treatment plans, please go to a regular hospital for treatment.